Positive Phase III Results of Genentech’s Actemra (Tocilizumab) for the Treatment of Giant Cell Arteritis Published in New England Journal of Medicine

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that data from the Phase III GiACTA study, which evaluated Actemra® (tocilizumab) in adult patients with GCA, were published in the July 27, 2017 issue of the New England Journal of Medicine. The primary endpoint of the study was met; Actemra combined with a 26-week steroid taper regimen showed superiority in achieving sustained remission at 52 weeks (56 percent [Ac

Full Story →